Picture1.jpg
Oncotelic Therapeutics Announces Clinical Linkage of TGFB2 and IFNGR2 in Pediatric DMG Patients
January 16, 2024 08:00 ET | Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today the peer reviewed publication of Transforming Growth Factor Beta 2 (TGFB2) and...
Picture1.jpg
Oncotelic Therapeutics Announces CEO To Discuss Proprietary AI Technology at Ibero-American Chatbot Summit.
November 28, 2023 07:10 ET | Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), announced today its Chief Executive Officer (“CEO”),...
Picture1.jpg
Oncotelic Reports Q3 2023 Compared to Q3 2022 Financial Results
November 15, 2023 09:00 ET | Oncotelic Therapeutics, Inc.
R&D cost remains essentially unchanged, while continuing expansion of our OT-101 clinical programs through our joint venture (“JV”)G&A cost significantly lower by over approximately $0.5...
Picture1.jpg
Oncotelic Therapeutics, Inc. Awarded Top Cancer Immunotherapy Solutions Provider 2023
August 25, 2023 07:00 ET | Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Aug. 25, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), announced today it was featured in Life Sciences...
Picture1.jpg
Sapu BioScience and Cromos Pharma initiating P201 – A Registrational trial for OT-101 in Pancreatic Cancer
August 23, 2023 07:10 ET | Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), announced today its joint venture partner, GMP...
Picture1.jpg
Oncotelic Launches PR Chatbot
June 12, 2023 08:10 ET | Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), annouces the beta unveiling of a pioneering press...
Picture1.jpg
Oncotelic Launches PDAO SEC Chatbot
April 24, 2023 07:30 ET | Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), , today announced the beta launch of a proprietary...
Picture1.jpg
Oncotelic Therapeutics and Vectara Announce Strategic Partnership to Transform Pharmaceutical Research with Large Language Model Technology
April 19, 2023 08:00 ET | Oncotelic Therapeutics, Inc.
The companies are executing on the shared vision of utilizing AI for effective knowledge management in the pharmaceutical research and development industry. AGOURA HILLS, Calif., April 19, 2023 ...
Picture1.jpg
ONCOTELIC PROVIDES YE 2022 FINANCIAL RESULTS COMPARED TO YE 2021 PRODUCT DEVELOPMENT INITIATIVES AND CORPORATE UPDATE
April 17, 2023 07:00 ET | Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic”, “We” or the “Company”) (OTCQB:OTLC) is providing a summary of its financial results for the year...
Picture1.jpg
Oncotelic Announces Release of Pet2DAO Tokens (PDAO)
April 03, 2023 07:00 ET | Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a developer of treatments for rare and orphan indications,...